More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.

The Food and Drug Administration (FDA) has approved Fasenra ® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...

AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...

That changed on Tuesday however, as the FDA signed off on Fasenra for patients with eosinophilic granulomatosis with ...

AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated ...

Neurological disorders are disorders that affect the central nervous system or the peripheral nervous systems and can impair the brain, spinal cord, peripheral nerve or neuromuscular function.

CALY-002 is under development for the treatment of eosinophilic esophagitis, celiac disease and unspecified dermatological disorders. It is a fully-humanized monoclonal antibody also administered ...

Since EGE is a heterogeneous disorder, we next assessed the relationship ... EGE (Table 1), while involvement of multiple organs by eosinophilic infiltration was seen in 52.2% (12/23) of those ...

NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit up to 100 people. Looking back over the journey from our humble beginnings ...

Eosinophilic esophagitis is a chronic immune disorder that affects the esophagus. The esophagus is the muscular tube that connects the mouth to the stomach and brings food into the body. In ...